Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have earned an average rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $15.50.
Several analysts have commented on BCRX shares. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. JMP Securities reissued a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Needham & Company LLC upped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Evercore ISI lifted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Barclays increased their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th.
BioCryst Pharmaceuticals Price Performance
Institutional Investors Weigh In On BioCryst Pharmaceuticals
Several institutional investors have recently bought and sold shares of BCRX. Vanguard Group Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Geode Capital Management LLC grew its position in BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after purchasing an additional 127,708 shares in the last quarter. Fisher Asset Management LLC lifted its position in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock worth $25,369,000 after buying an additional 481,359 shares in the last quarter. Caligan Partners LP boosted its stake in shares of BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company’s stock worth $22,529,000 after buying an additional 412,347 shares during the last quarter. Finally, Two Sigma Advisers LP grew its holdings in shares of BioCryst Pharmaceuticals by 14.6% in the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company’s stock valued at $18,799,000 after acquiring an additional 318,800 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
See Also
- Five stocks we like better than BioCryst Pharmaceuticals
- Profitably Trade Stocks at 52-Week Highs
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.